Nuochen Jianhua: The CDH17-targeted ADC innovative drug ICP-B208 has been approved for clinical trials.

On May 7th, Nuocheng Jianhua announced that its self-developed novel ADC targeting CDH17, ICP-B208, has been approved by the National Medical Products Administration's Drug Evaluation Center to conduct clinical research.